Determination of Seminal Concentration of Fingolimod and Fingolimod-Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod

David, OJ; Berwick, A; Pezous, N; Lang, M; Tiel-Wilck, K; Ziemssen, T; Li, P; Hara, H; Schmouder, R

David, OJ (reprint author), Novartis Pharma AG, Novartis Campus, CH-4056 Basel, Switzerland.

CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2018; 7 (2): 217

Abstract

The safety profile of fingolimod 0.5mg, approved therapy for relapsing multiple sclerosis, is well established in clinical and real-world studies. As ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索